Personalized medicine in the sense of individualized therapy concepts plays an 
important role in breast cancer. In early breast cancer the molecular subtypes 
luminal A and B and basal-like are important for planning adjuvant systemic 
therapy. Prognostic and predictive markers, such as hormone receptor status, 
HER2, Ki-67, uPA/PAI-1 or multiple gene tests, such as Oncotype DX® currently 
allow avoidance of an over therapy or under therapy. In early and also advanced 
breast cancer there are an increasing number of new targeted therapies which 
represent an augmentation of standard endocrine and chemotherapy and in the 
future could at least partially replace them. As a whole the therapy regimens 
for breast cancer have become more complex due to the inclusion of molecular 
information, new therapies and the withdrawal of conventional treatment 
concepts. Decisive for the future will be the confirmation of this development 
by modern study concepts contemporarily with adequate evidence. It could then be 
expected that a personalized therapy for early breast cancer and in particular 
adjuvant chemotherapy would only be used for those patients for whom it is 
really necessary. In advanced stage disease there is justified hope that the 
survival time in the sense of a chronic disease can be improved by the use of 
targeted therapy.